Advertisement

Topics

Hikma upping injectables capacity by as much as 500% by end of 2017

10:53 EDT 22 Aug 2017 | in-PharmaTechnologis

Hikma has ramped up capacity at manufacturing facilities in the US and Portugal manufacturing to meet the growing demand for its lyophilised and oncology products.

Original Article: Hikma upping injectables capacity by as much as 500% by end of 2017

NEXT ARTICLE

More From BioPortfolio on "Hikma upping injectables capacity by as much as 500% by end of 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...